Richard A. Rudick Mellen Center for Multiple Sclerosis Treatment and Research Cleveland Clinic Foundation Biography Publications Institution JoVE Articles Richard A. Rudick has not added a biography. If you are Richard A. Rudick and would like to personalize this page please email our Author Liaison for assistance. Publications Long-term Safety and Effectiveness of Natalizumab Redosing and Treatment in the STRATA MS Study Neurology. Jun, 2014 | Pubmed ID: 24898925 Defining the Clinical Course of Multiple Sclerosis: The 2013 Revisions Neurology. May, 2014 | Pubmed ID: 24871874 Assessing Treatment Response to Interferon-β: is There a Role for MRI? Neurology. Jan, 2014 | Pubmed ID: 24336144 Multiple Sclerosis Outcome Assessments Consortium: Genesis and Initial Project Plan Multiple Sclerosis (Houndmills, Basingstoke, England). Jan, 2014 | Pubmed ID: 24057430 Preventing Brain Atrophy Should Be the Gold Standard of Effective Therapy in MS (after the First Year of Treatment): Yes Multiple Sclerosis (Houndmills, Basingstoke, England). Jul, 2013 | Pubmed ID: 23818018 MRI Lesions: a Surrogate for Relapses in Multiple Sclerosis? Lancet Neurology. Jul, 2013 | Pubmed ID: 23743083 Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic JAMA Neurology. Mar, 2013 | Pubmed ID: 23599930 Author Response to Comment on "time to Integrate Clinical and Research Informatics" Science Translational Medicine. Apr, 2013 | Pubmed ID: 23552368 Author Response Neurology. Feb, 2013 | Pubmed ID: 23544194 Predictors of Long-term Outcome in Multiple Sclerosis Patients Treated with Interferon β Annals of Neurology. Jan, 2013 | Pubmed ID: 23378325 Time to Integrate Clinical and Research Informatics Science Translational Medicine. Nov, 2012 | Pubmed ID: 23197569 Measurement and Clinical Effect of Grey Matter Pathology in Multiple Sclerosis Lancet Neurology. Dec, 2012 | Pubmed ID: 23153407 Early Tolerability and Safety of Fingolimod in Clinical Practice Journal of the Neurological Sciences. Dec, 2012 | Pubmed ID: 23040960 Multiple Sclerosis or Multiple Possibilities: the Continuing Problem of Misdiagnosis Neurology. Jun, 2012 | Pubmed ID: 22581931 The Elusive Biomarker for Personalized Medicine in Multiple Sclerosis: the Search Continues Neurology. Aug, 2012 | Pubmed ID: 22573625 MS Clinical Trials: What Can Subgroup Analyses Teach Us? Lancet Neurology. May, 2012 | Pubmed ID: 22494954 Risk Stratification and Patient Counseling for Natalizumab in Multiple Sclerosis Neurology. Feb, 2012 | Pubmed ID: 22282644 Multiple Sclerosis, Natalizumab, and PML: Helping Patients Decide Cleveland Clinic Journal of Medicine. Nov, 2011 | Pubmed ID: 22123928 The Role of Cell Type-specific Responses in IFN-β Therapy of Multiple Sclerosis Proceedings of the National Academy of Sciences of the United States of America. Dec, 2011 | Pubmed ID: 22106296 Oral Treatment for Multiple Sclerosis Lancet Neurology. Nov, 2011 | Pubmed ID: 22014437 Excessive Biologic Response to IFNβ is Associated with Poor Treatment Response in Patients with Multiple Sclerosis PloS One. 2011 | Pubmed ID: 21602934 Challenges to Clinical Trials in Multiple Sclerosis: Outcome Measures in the Era of Disease-modifying Drugs Current Opinion in Neurology. Jun, 2011 | Pubmed ID: 21455068 Beta-interferon for Multiple Sclerosis Experimental Cell Research. May, 2011 | Pubmed ID: 21396360 Diagnostic Criteria in Multiple Sclerosis: Headed in the Right Direction but Still a Ways to Go Annals of Neurology. Feb, 2011 | Pubmed ID: 21387367 Web-based Self-management for Patients with Multiple Sclerosis: a Practical, Randomized Trial Telemedicine Journal and E-health : the Official Journal of the American Telemedicine Association. Jan-Feb, 2011 | Pubmed ID: 21214498 Possible Clinical Outcome Measures for Clinical Trials in Patients with Multiple Sclerosis Therapeutic Advances in Neurological Disorders. Jul, 2010 | Pubmed ID: 21179614 Multiple Sclerosis: is Multiple Sclerosis Caused by Venous Insufficiency? Nature Reviews. Neurology. Sep, 2010 | Pubmed ID: 20811464 Assessment of JC Virus DNA in Blood and Urine from Natalizumab-treated Patients Annals of Neurology. Sep, 2010 | Pubmed ID: 20737514 Disability Progression in a Clinical Trial of Relapsing-remitting Multiple Sclerosis: Eight-year Follow-up Archives of Neurology. Nov, 2010 | Pubmed ID: 20625068 Measuring Disability in Relapsing-remitting MS Neurology. Jul, 2010 | Pubmed ID: 20592252 Validation of a Self-report Comorbidity Questionnaire for Multiple Sclerosis Neuroepidemiology. Aug, 2010 | Pubmed ID: 20551692 The Multiple Sclerosis Functional Composite: a Clinically Meaningful Measure of Disability Neurology. Apr, 2010 | Pubmed ID: 20421572 Patient-centered Outcomes: Translating Clinical Efficacy into Benefits on Health-related Quality of Life Neurology. Apr, 2010 | Pubmed ID: 20421570 Natalizumab Plus Interferon Beta-1a Reduces Lesion Formation in Relapsing Multiple Sclerosis Journal of the Neurological Sciences. May, 2010 | Pubmed ID: 20236661 A Radical Proposal: Integrate Clinical Investigation into the U.S. Health Care System Science Translational Medicine. Oct, 2009 | Pubmed ID: 20368168 Heterogeneous, Longitudinally Stable Molecular Signatures in Response to Interferon-beta Annals of the New York Academy of Sciences. Dec, 2009 | Pubmed ID: 20074275 Do Interferon Beta-1b and Glatiramer Acetate Grow Brain? Lancet Neurology. Dec, 2009 | Pubmed ID: 19909906 Gray-matter Injury in Multiple Sclerosis The New England Journal of Medicine. Oct, 2009 | Pubmed ID: 19812410 Current Approaches to the Identification and Management of Breakthrough Disease in Patients with Multiple Sclerosis Lancet Neurology. Jun, 2009 | Pubmed ID: 19446274 The Efficacy of Natalizumab in Patients with Relapsing Multiple Sclerosis: Subgroup Analyses of AFFIRM and SENTINEL Journal of Neurology. Mar, 2009 | Pubmed ID: 19308305 Brain Atrophy As an Outcome Measure for Multiple Sclerosis Clinical Trials: a "no-brainer"? Neurology. Feb, 2009 | Pubmed ID: 19221291 Gray Matter Atrophy Correlates with MS Disability Progression Measured with MSFC but Not EDSS Journal of the Neurological Sciences. Jul, 2009 | Pubmed ID: 19100997 Natalizumab for the Treatment of Relapsing Multiple Sclerosis Biologics : Targets & Therapy. Jun, 2008 | Pubmed ID: 19707353 Health-related Quality of Life in Multiple Sclerosis: Current Evidence, Measurement and Effects of Disease Severity and Treatment CNS Drugs. 2008 | Pubmed ID: 18788835 LINGO-1 Antagonists As Therapy for Multiple Sclerosis: in Vitro and in Vivo Evidence Expert Opinion on Biological Therapy. Oct, 2008 | Pubmed ID: 18774923 Gray Matter Atrophy in Multiple Sclerosis: a Longitudinal Study Annals of Neurology. Sep, 2008 | Pubmed ID: 18661561 Biomarkers for Interferon Response in MS: Are We There Yet? Neurology. Mar, 2008 | Pubmed ID: 18362268 Interferon-beta Treatment for Multiple Sclerosis Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics. Oct, 2007 | Pubmed ID: 17920544 Novel Interferon-beta-induced Gene Expression in Peripheral Blood Cells Journal of Leukocyte Biology. Nov, 2007 | Pubmed ID: 17709400 Health-related Quality of Life in Multiple Sclerosis: Effects of Natalizumab Annals of Neurology. Oct, 2007 | Pubmed ID: 17696126 Developing a Mentorship Program for Clinical Researchers The Journal of Continuing Education in the Health Professions. 2007 | Pubmed ID: 17576629 Interferon-beta for Multiple Sclerosis: Long-term Benefits? Annals of Neurology. Apr, 2007 | Pubmed ID: 17444503 Natalizumab Treatment for Multiple Sclerosis: Recommendations for Patient Selection and Monitoring Lancet Neurology. May, 2007 | Pubmed ID: 17434098 Imaging Correlates of Axonal Swelling in Chronic Multiple Sclerosis Brains Annals of Neurology. Sep, 2007 | Pubmed ID: 17427920 Disease Modification in Multiple Sclerosis: Issues with Relevance to Clinical Trial Designs in Alzheimer's Disease Alzheimer's & Dementia : the Journal of the Alzheimer's Association. Jul, 2006 | Pubmed ID: 19595872 Chemokine Receptors As Biomarkers in Multiple Sclerosis Disease Markers. 2006 | Pubmed ID: 17124344 Drug Insight: Interferon Treatment in Multiple Sclerosis Nature Clinical Practice. Neurology. Jan, 2006 | Pubmed ID: 16932519 Significance of T2 Lesions in Multiple Sclerosis: A 13-year Longitudinal Study Annals of Neurology. Aug, 2006 | Pubmed ID: 16786526 Natalizumab Plus Interferon Beta-1a for Relapsing Multiple Sclerosis The New England Journal of Medicine. Mar, 2006 | Pubmed ID: 16510745 Should Patients with Relapsing Multiple Sclerosis Be Given a Higher Dose and Frequency of Interferon-beta1a? Nature Clinical Practice. Neurology. Nov, 2005 | Pubmed ID: 16932486 Prediction of Longitudinal Brain Atrophy in Multiple Sclerosis by Gray Matter Magnetic Resonance Imaging T2 Hypointensity Archives of Neurology. Sep, 2005 | Pubmed ID: 16157744 Primary Progressive Multiple Sclerosis As a Phenotype of a PLP1 Gene Mutation Annals of Neurology. Sep, 2005 | Pubmed ID: 16130097 Effects of Sex Hormones on Costimulatory Molecule Expression in Multiple Sclerosis Journal of Neuroimmunology. Oct, 2005 | Pubmed ID: 16046001 Eight-year Immunogenicity and Safety of Interferon Beta-1a-Avonex Treatment in Patients with Multiple Sclerosis Multiple Sclerosis (Houndmills, Basingstoke, England). Aug, 2005 | Pubmed ID: 16042223 Brain Atrophy and Magnetization Transfer Ratio Following Methylprednisolone in Multiple Sclerosis: Short-term Changes and Long-term Implications Multiple Sclerosis (Houndmills, Basingstoke, England). Apr, 2005 | Pubmed ID: 15794385 Association of Fatigue and Brain Atrophy in Multiple Sclerosis Journal of the Neurological Sciences. Feb, 2005 | Pubmed ID: 15694198 Natalizumab: Alpha 4-integrin Antagonist Selective Adhesion Molecule Inhibitors for MS Expert Review of Neurotherapeutics. Jul, 2004 | Pubmed ID: 15853576 Defining Interferon Beta Response Status in Multiple Sclerosis Patients Annals of Neurology. Oct, 2004 | Pubmed ID: 15389896 Impact of Disease-modifying Therapies on Brain and Spinal Cord Atrophy in Multiple Sclerosis Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. Jul, 2004 | Pubmed ID: 15228760 Multiple Sclerosis: Disease Markers Accelerate Progress Lancet Neurology. Jan, 2004 | Pubmed ID: 14693099 Atrophy is Detectable Within a 3-month Period in Untreated Patients with Active Relapsing Remitting Multiple Sclerosis Archives of Neurology. Dec, 2003 | Pubmed ID: 14676048 Biologic Impact of Interferon Antibodies, and Complexities in Assessing Their Clinical Significance Neurology. Nov, 2003 | Pubmed ID: 14610110 Interferon-beta 1a Does Not Reduce Expression of CCR5 and CXCR3 on Circulating T Cells Journal of Neuroimmunology. Aug, 2003 | Pubmed ID: 12965266 Interferon Gamma Responses to Myelin Peptides in Multiple Sclerosis Correlate with a New Clinical Measure of Disease Progression Journal of Neuroimmunology. Aug, 2003 | Pubmed ID: 12965264 Interferons in Relapsing Remitting Multiple Sclerosis Lancet. May, 2003 | Pubmed ID: 12781561 Expression of CCR2, CCR5, and CXCR3 by CD4+ T Cells is Stable During a 2-year Longitudinal Study but Varies Widely Between Individuals Journal of Neurovirology. Jun, 2003 | Pubmed ID: 12775413 Flow Cytometric Analysis of Chemokine Receptor Expression on Cerebrospinal Fluid Leukocytes Methods (San Diego, Calif.). Apr, 2003 | Pubmed ID: 12725798 Factors That Predict Health-related Quality of Life in Patients with Relapsing-remitting Multiple Sclerosis Multiple Sclerosis (Houndmills, Basingstoke, England). Feb, 2003 | Pubmed ID: 12617260 Sex Differences in Cytokine Responses to Myelin Peptides in Multiple Sclerosis Journal of Neuroimmunology. Sep, 2002 | Pubmed ID: 12225904 The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool Richard A. Rudick1, Deborah Miller1, Francois Bethoux1, Stephen M. Rao2, Jar-Chi Lee3, Darlene Stough1, Christine Reece2, David Schindler4, Bernadett Mamone1, Jay Alberts4 1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, 2Center for Brain Health, Cleveland Clinic Foundation, 3Quantitative Health Sciences, Cleveland Clinic Foundation, 4Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation JoVE 51318 Médecine
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool Richard A. Rudick1, Deborah Miller1, Francois Bethoux1, Stephen M. Rao2, Jar-Chi Lee3, Darlene Stough1, Christine Reece2, David Schindler4, Bernadett Mamone1, Jay Alberts4 1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, 2Center for Brain Health, Cleveland Clinic Foundation, 3Quantitative Health Sciences, Cleveland Clinic Foundation, 4Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation JoVE 51318 Médecine